Mibefradil (Ro 40-5967): the first selective T-type Ca2+ channel blocker

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Discovery

Background:

• Mibefradil is a novel calcium (Ca2+) antagonist.
• It selectively targets both L-type and T-type Ca2+ channels, with a ten-fold greater affinity for T-type channels.
• Belongs to a unique chemical class (tetralol derivative) and interacts with a distinct receptor site on L-type Ca2+ channels.

Purpose of the Study:

• To evaluate the pharmacological properties and clinical efficacy of mibefradil.
• To investigate its selectivity for vascular beds and effects on cardiac function.
• To assess its potential in treating hypertension, angina, and heart failure.

Main Methods:

• In vitro and in vivo studies assessing vascular selectivity and inotropic effects.
• Clinical trials in normotensive and hypertensive patients, including those with angina pectoris.
• Pharmacokinetic and safety profiling.

Main Results:

• Mibefradil demonstrates high selectivity for coronary over peripheral vasculature and myocardium.
• It exhibits no significant negative inotropic effects; instead, it slightly decreases heart rate and improves cardiac function.
• Clinical studies confirm efficacy as an antihypertensive and anti-ischaemic agent, with potential benefits in heart failure.

Conclusions:

• Mibefradil possesses a unique pharmacological profile, largely attributed to its selective T-type Ca2+ channel blockade.
• Its favorable efficacy, safety, and pharmacokinetic profile make it a promising therapeutic agent.
• Mibefradil shows potential for treating a range of cardiovascular conditions, including hypertension, angina, and heart failure.